Patents by Inventor Amnon Peled
Amnon Peled has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11261159Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.Type: GrantFiled: August 10, 2020Date of Patent: March 1, 2022Assignee: AlonBio Ltd.Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
-
Publication number: 20220008407Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or inhibiting a kinase and/or in treating a disease or disorder associated with an activity of a kinase, such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B D, E, G and R1-R5 are as defined in the specification.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: Biokine Therapeutics Ltd.Inventors: Amnon PELED, Michal ABRAHAM KARNI, Orly EIZENBERG
-
Publication number: 20220010016Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.Type: ApplicationFiled: October 17, 2019Publication date: January 13, 2022Applicants: BioLineRx Ltd., Merck Sharp & Dohme Corp.Inventors: Abi VAINSTEIN-HARAS, Ella SORANI, Irit GLIKO-KABIR, Osnat BOHANA-KASHTAN, Amnon PELED
-
Publication number: 20210338767Abstract: A method of selecting a treatment regimen for a subject diagnosed with a cancer is provided. The method comprising, determining in cancer cells of said subject, CXCR4 occupancy in a presence and an absence of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof, wherein an increase above a predetermined threshold in said CXCR4 occupancy in said presence of said peptide as compared to said absence of said peptide is indicative of suitability of said subject to treatment with said peptide, or analog or derivative.Type: ApplicationFiled: September 25, 2019Publication date: November 4, 2021Applicants: BioLineRx Ltd., Biokine Therapeutics Ltd.Inventors: Osnat BOHANA-KASHTAN, Stephen Michael SHAW, Amnon PELED
-
Patent number: 11129824Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or inhibiting a kinase and/or in treating a disease or disorder associated with an activity of a kinase, such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B D, E, G and R1-R5 are as defined in the specification.Type: GrantFiled: December 15, 2016Date of Patent: September 28, 2021Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Abraham, Orly Eizenberg
-
Publication number: 20210228535Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.Type: ApplicationFiled: March 29, 2021Publication date: July 29, 2021Applicant: Biokine Therapeutics Ltd.Inventors: Amnon PELED, Michal ABRAHAM KARNI, Orly EIZENBERG
-
Patent number: 10993985Abstract: A method of treating acute myeloid leukemia (AML), including the steps of (i) measuring a density of blast cells in the peripheral blood and the bone marrow of a subject with AML; (ii) administering to the subject a CXCR4 antagonist; and (iii) administering to the subject a therapeutically effective amount of the CXCR4 antagonist and a therapeutically effective amount of a chemotherapeutic agent, if the blast cell density in the peripheral blood is less than 10% of the total peripheral white blood cells, or at least five-fold lower than the blast cell density in the bone marrow, or at least two-fold higher one day or more following step (ii).Type: GrantFiled: February 23, 2017Date of Patent: May 4, 2021Assignees: BioLmeRx Ltd., Biokine Therapeutics Ltd.Inventors: Yaron Pereg, Amnon Peled
-
Patent number: 10959979Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.Type: GrantFiled: May 7, 2020Date of Patent: March 30, 2021Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
-
Publication number: 20200390855Abstract: A method of treating cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and an anti-cancer agent, thereby treating the cancer in the subject.Type: ApplicationFiled: August 31, 2020Publication date: December 17, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200369617Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.Type: ApplicationFiled: August 10, 2020Publication date: November 26, 2020Applicant: Biokine Therapeutics Ltd.Inventors: Amnon PELED, Michal ABRAHAM KARNI, Orly EIZENBERG
-
Patent number: 10786547Abstract: A method of treating cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and an anti-cancer agent, thereby treating the cancer in the subject.Type: GrantFiled: July 14, 2016Date of Patent: September 29, 2020Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Publication number: 20200297809Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297810Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297806Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297807Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx LtdInventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297802Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an MO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297804Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297812Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297808Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG
-
Publication number: 20200297803Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: ApplicationFiled: May 5, 2020Publication date: September 24, 2020Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon PELED, Yaron PEREG